Vaccine Info

Shingles Vaccines 2022

Authored by
Last reviewed
April 6, 2022

Shingles Vaccines For 2022

Shingles (Herpes Zoster) is caused by the varicella-zoster virus (VZV), the same virus that causes chickenpox, says the U.S. CDC. After a person recovers from chickenpox, the virus stays dormant (inactive) in the body. However, this virus can reactivate years later, causing shingles.

About 1 out of every three people in the United States will develop shingles. An estimated 1 million people get shingles each year in the U.S. If you've ever had chickenpox, you can get shingles. Even children can get shingles. Your risk of shingles increases as you get older, as well as serious complications, says the U.S. NIH.

According to the CDC, symptoms can include pain, itching, or tingling of the skin followed by a painful rash of blister-like sores, usually on one side of the body, often on the face or torso. This disease can also include fever, headache, chills, and an upset stomach. published updated FAQs regarding shingles vaccination.

Shingles Vaccines for 2022

There are U.S. FDA-authorized Shingles vaccines for use in the United States. And the CDC recently (Feb. 17, 2022) published updated vaccination schedules for 2022.

Shingrix - GSK's Shingrix is a non-live, adjuvanted recombinant shingles vaccine (zoster) consisting of the varicella-zoster virus glycoprotein E antigen and the AS01B adjuvant system, a proprietary adjuvant containing QS-21 and MPL with liposomes.

Zostavax - Merck's Zostavax is a live, attenuated varicella-zoster virus (weakened chickenpox virus) vaccine. According to the U.S. CDC, the zoster vaccine can be administered concurrently with all other live and inactivated vaccines, including those routinely recommended for people 60 years of age or older, such as influenza and pneumococcal vaccines.

Shingles Vaccine Candidates for 2022

CRV-101 - Curevo Vaccine's CRV-101 is a next-generation shingles vaccine candidate designed to maximize CMI protection by combining the gE protein antigen with our proprietary adjuvant.

Pfizer and BioNTech are developing an mRNA vaccine for shingles. Clinical trials are planned to start in the second half of 2022

Shingles Vaccine News For 2019 - 2022

April 3, 2022 - A retrospective cohort study found adults (50 yrs+) with COVID-19 had a 15% increased risk of developing herpes zoster.

April 1, 2022 - Aurobindo Pharma Limited received final approval from U.S. FDA for its Abbreviated New Drug Application Acyclovir Oral Suspension USP, 200 mg/5 mL. Aurobindo Pharma’s Acyclovir Oral Suspension; an AB-rated generic equivalent to the reference listed drug (RLD), ZOVIRAX ® (acyclovir), of Mylan Pharmaceuticals Inc. Acyclovir Oral Suspension are indicated for: Acute treatment of herpes zoster (shingles), Treatment of initial episodes and the management of recurrent episodes of genital herpes, and the treatment of chickenpox (varicella).

March 25, 2022 - Consumer Reports published an article: The Booster Shots You Need As an Adult. The shingles vaccine isn't commonly referred to as a booster, but it does count as one because it reminds your body how to fight the varicella-zoster virus.

March 14, 2022 - GreenLight Biosciences Holdings PBC announced a licensing agreement with Serum Institute of India, Pvt, Ltd., to accelerate access to messenger RNA products (Shingles) in emerging markets.

March 10, 2022 - The U.S. FDA confirmed GSK completed its recall of 130,000 doses of Shingrix.

March 3, 2022 - Are You Aware of Your Shingles Risk?

February 28, 2022 - GSK launched the inaugural Shingles Awareness Week to educate the general public about shingles in collaboration with the International Federation on Ageing.

February 25, 2022 - GSK wrote the mysterious reactivation (of VZV) was studied for the first time by a doctor in Cirencester, England, more than half a century ago. By tracking 1,270 patients from 1947 to 1962, R. Edgar Hope-Simpson demonstrated that shingles were not a new infection from an unknown pathogen but rather a reawakening of the VZV.

July 14, 2020 - Shingles Vaccination Rates Significantly Increased With Seniors.

February 13, 2020 - Shingles Vaccination Reduced Stroke Risk By 16%.

September 26, 2019 - Curevo, Inc. announced encouraging preliminary Phase I study results of their Shingles vaccine candidate, CRV-101. 

May 23, 2019 - GlaxoSmithKline plc announced that China's National Medical Products Administration approved Shingrix to prevent shingles in adults aged 50 years or older.


Note: This page aggregates and edits content for clarity and was manually curated for mobile readers.

Clinical Trials

No clinical trials found